Companies / enGene Therapeutics Inc.
enGene Therapeutics Inc.
Nasdaq: ENGNCIK 1980845SAINT-LAURENT
Financials
Ownership
67.0M shares outstanding · as of Jun 9, 2026
Ownership
| 10%+ / strategic | 18.16% | 12,162,806 |
| Institutions | 92.03% | 61,651,647 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 13
View all →| Insider | % of shares | Shares |
|---|---|---|
Astley-Sparke PhilipDirector | — | — |
Boyd Matthew RossChief Regulatory Officer | — | — |
Brunk Gerald aDirector | — | — |
Buck JillChief Development Officer | — | — |
Cheung Anthony TzeyewChief Scientific Officer | — | — |
Connolly JoanChief Technology Officer | — | — |
Cooper Ronald Harold WilfredCEOCEO & President · Director | — | — |
Daws D. RyanChief Financial Officer | — | — |
Giguere LeeChief Legal Ofc. and Corp Secy | — | — |
Glickman Richard MDirector | — | — |
Institutional holders 61
View all →| Holder | Value | % of shares |
|---|---|---|
| $86.98M | 14.38% | |
| $43.09M | 7.12% | |
| $39.69M | 8.70% | |
| $39.53M | 6.53% | |
| $36.12M | 5.97% | |
| $30.35M | 5.02% | |
| $30.13M | 4.98% | |
| $28.28M | 4.67% | |
| $19.19M | 3.17% | |
| $17.11M | 2.84% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Brunk Gerald a Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Astley-Sparke Philip Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Glickman Richard M Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Hastings Paul J Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Zoth Lota S. Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jan 30, 2026 | Cheung Anthony Tzeyew Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Nichols Alexander Julian Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Connolly Joan Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Cormorant Asset Management, LP | Passive13G | — |
| Venrock Healthcare Capital Partners III, L.P. | Passive13G/A | — |
| Kynam Capital Management, LP | Passive13G/A | — |
| Invus, L.P. | Passive13G | — |
| BML Investment Partners, L.P. | Passive13G/A | — |
| BML Investment Partners, L.P. | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| ENGN | Common Stock | 29286X101 |
| ENGN | — | 29286M105 |